Back to Search Start Over

Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.

Authors :
Chang, Chen
Lin, Ching‐Hung
Cheng, Ann‐Lii
Medeiros, L Jeffrey
Chang, Kung‐Chao
Source :
Histopathology; Nov2015, Vol. 67 Issue 5, p625-635, 11p, 1 Color Photograph, 2 Charts, 1 Graph
Publication Year :
2015

Abstract

Aims Primary central nervous system ( CNS) diffuse large B-cell lymphoma ( PCNSL) is an ominous disease with a poor prognosis. The brain is an immune-privileged sanctuary, and this may contribute to an ineffective host immune response and thus a poorer outcome. The aim of this study was therefore to study the difference in the immune composition in PCNSL and non- CNS diffuse large B-cell lymphoma ( DLBCL), and the role of the immune response in PCNSL prognosis. Methods and results Thirty-two biopsy specimens of PCNSL and 30 specimens of low-stage non- CNS DLBCL from immunocompetent patients formed the study group. The density and distribution of immune cells, including dendritic cells (dendritic cell-specific lysosomal-associated membrane protein-positive and S100-positive), effector/memory T cells ( CD45 RO-positive), and cytotoxic T cells (granzyme B-positive), and the expression of HLA- DR by lymphoma cells, were evaluated immunohistochemically. PCNSL patients showed poorer overall survival ( P = 0.032). On comparison of the PCNSL and DLBCL biopsy specimens, the PCNSL cells showed less HLA- DR expression ( P = 0.003), and there were fewer S100-positive cells ( P < 0.01), and effector T cells ( P = 0.026) infiltrating PCNSL than infiltrating DLBCL. For PCNSL patients, fewer cytotoxic T cells in the background constituted a poor prognostic factor ( P = 0.004). Intratumoral S100-positive cell infiltration was positively correlated with T-cell infiltration, and a T-cell rimming pattern. Conclusions In PCNSL, the baseline antitumour immune response is less as compared with non- CNS DLBCL, and this response may play a role in the poorer prognosis. Adjuvant dendritic cell and T-cell immunotherapy may further boost treatment responses in PCNSL patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03090167
Volume :
67
Issue :
5
Database :
Complementary Index
Journal :
Histopathology
Publication Type :
Academic Journal
Accession number :
110221836
Full Text :
https://doi.org/10.1111/his.12706